References

1.     Arbel, R. et al, Effectiveness of a single-doseModified Vaccinia Ankara in Human Monkeypox: an observational study DOI.Available from: https://doi.org/10.21203/rs.3.rs-1976861/v2 

2.     Payne AB, Ray LC, Cole MM et al. Reduced Risk for Mpoxafter Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk AmongUnvaccinated Persons-43 U.S- Jurisdictions, July 31-October1, 2022. MMWRDecember 9, 2022/Vol. 71/No.49 

3.     Pischel L,Martini BA, Yu N, et al. Vaccine effectiveness of 3rd generation mpox vaccinesagainst mpox and disease severity: A systematic review and meta-analysis.Vaccine, 2024. Available from: https://doi.org/10.1016/j.vaccine.2024.06.021

4.     Payne AB,Ray LC, Kugeler KJ, et al. Incidence of Monkeypox Among Unvaccinated PersonsCompared with Persons Receiving >/=1 JYNNEOS Vaccine Dose - 32 U.S.Jurisdictions, July 31-September 3, 2022. MMWR Morb Mortal Wkly Rep, 2022.71(40): p. 1278-1282.

5.     US Food and Drug Administration. JYNNEOS- FULLPRESCRIBING INFORMATION Package Insert. 2018. Available from: https://www.fda.gov/media/131078/download 

6.     Greenberg, R.N. et al, A Multicenter, Open-Label,Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA SmallpoxVaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.PLOS ONE, 2015. 10 (10):p e0138348 

7.     Dashraath, P. et al. Guidelines for pregnantindividuals with monkeypox virus exposure. Lancet June 21, 2022. Availablefrom: https://doi.org/10.1016/S0140-6736(22)01063-7 

8.     Greenberg, R.N. et al Safety, Immunogenicity, andSurrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as aSmallpox Vaccine in HIV-Infected Subjects. The Journal of Infectious Diseases2013;207:749–58

‍